Biotechnology News & Press Release Distribution

Biotechnology

APAC
Global

I-Mab to Participate at the Piper Sandler Healthcare Conference

The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, Md., Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treat...

2024-11-21 20:00 506

SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland, Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IM...

2024-11-21 18:30 483

111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024

SHANGHAI, Nov. 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will part...

2024-11-21 18:00 552

InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against cancer treatment resistance and metastasis, announced that China National Medical Products Administration (NMPA) has granted Ifebemtinib (IN10018) Breakthr...

2024-11-21 15:09 1054

DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation

This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time. BEIJING, Nov. 20, 2024 /PRNewswi...

2024-11-21 13:01 776

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including$420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead...

2024-11-21 06:00 1101

GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products

PLANTATION, Fla., Nov. 21, 2024 /PRNewswire/ -- GBI Biomanufacturing (GBI), one of the world's longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expansion of its Drug Product (DP)services, to include automated sterile fill and finish capabilit...

2024-11-21 01:00 748

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity

The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preservingweight loss in Obesity LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech compan...

2024-11-20 22:00 1213

CABIO Deepens Commitment to Global Markets, Aiming to Serve International Clients and Pursue Long-Term International Partnerships

FRANKFURT, Germany, Nov. 20, 2024 /PRNewswire/ -- CABIO, a high-tech enterprise underpinned by biotechnology and listed on the Science and Technology Innovation Board (stock code: 688089), unveiled its innovative product, NeoHMOs®, at the Food Ingredients Europe event held inFrankfurt, Germany. ...

2024-11-20 21:00 626

CABIO Deepens Commitment to Global Markets, Aiming to Serve International Clients and Pursue Long-Term International Partnerships

2024 Global Healthy Longevity Conference Successfully Held

SHENZHEN, China, Nov. 20, 2024 /PRNewswire/ -- The 2024 Global Healthy Longevity Conference took place successfully in Shenzhen from 15-17 November. Under the theme "The Healthy Longevity Era: Technology-driven Anti-Aging," the conference combined exhibitions and forum presentations to explore ke...

2024-11-20 19:13 800

Samsung Biologics signs manufacturing deal with European pharmaceutical company

* The company will provide manufacturing services through 2031 in deals worth overUSD 668 million * Samsung Biologics' cumulative contract value for 2024 surpasses USD 4 billion with latest deals INCHEON, South Korea, Nov. 20, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global ...

2024-11-20 07:23 1121

Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B

SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA) from the New Zealand Medicines and Medical Devices Safe...

2024-11-20 07:20 1107

Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson's Research Through Development of Next Generation Biomarker Assays

FREMONT, Calif., Nov. 19, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to accelerate biomarker disco...

2024-11-19 22:12 1043

Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS

NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siR...

2024-11-19 21:26 978

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...

2024-11-19 20:30 804

Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA

48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to suppor...

2024-11-19 19:30 1511

SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player

* SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using analpha-particle emitting radioisotope, actinium-225, for potential cancer treatments * The two sides aim to submit an Investigatio...

2024-11-19 08:00 1501

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

MELBOURNE, Australia, Nov. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nucl...

2024-11-19 06:24 1407

C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital

CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding$100 million. This round ...

2024-11-18 22:00 1347

C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

* Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed$900M with tiered single digit sal...

2024-11-18 21:50 1183

12 3 4 5 ... 306

Week's Top Stories

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

[Picked up by 283 media titles]

2024-11-20 09:00